NMS is similar to other acute/subacute DRBA-induced movement disorders, in that VMAT2 inhibitors are likely to worsen symptoms, and they should be discontinued if NMS develops.74 When promptly diagnosed, symptoms most often resolve within 1 to 2 weeks after discontinuation of oral DRBAs.2,72 Some patients may benefit from supplemental treatment with benzodiazepines, dopaminergic drugs, muscle relaxants (eg, dantrolene), or even electroconvulsive therapy, although comparative controlled data are lacking and these agents are not approved to treat NMS.2 This evidence concerns the gene SLC18A2 and neuroleptic malignant syndrome.